Formulation and Drug Delivery

Gilead to Buy Kite Pharma for $11.9 Billion

August 29, 2017

Gilead will gain a robust pipeline of cell therapy products, with one lead candidate, a CAR T therapy, anticipated to gain FDA approval in the fourth quarter.

AstraZeneca and Takeda to Partner for PD Treatment

August 29, 2017

AstraZeneca and Takeda will partner to develop and commercialize MEDI1341, an alpha-synuclein antibody currently in development as a potential treatment for Parkinson’s disease (PD).

Sanofi Closes Acquisition of Protein Sciences

August 28, 2017

The acquisition of Protein Sciences, a vaccines biotechnology company, strengthens Sanofi’s influenza vaccines portfolio.

FDA Seizes Military Vaccine Used in Unauthorized Stem-Cell Treatments

August 28, 2017

FDA halts unproved stem-cell cancer treatments administered to California patients, which was derived from a commercially unavailable military-grade vaccine.

Alembic Sells Indian Formulations Plant

August 25, 2017

The generic pharmaceuticals firm has sold its Baddi, India formulations manufacturing facility following a recent fire at its joint-venture plant in Algeria.

Genentech Gets Priority Review for Hemophilia A Biologic

August 24, 2017

FDA grants priority review for emicizumab, an investigational bispecific monoclonal antibody, for treating hemophilia A with factor VIII inhibitors.

CPI Joins Consortium for Automated Continuous Biologics Purification

August 24, 2017

With £4.5 million (US$5.8 million) in funding, the consortium is tasked with developing a new automated continuous biologics purification unit to make biologic drug manufacturing more efficient.

Samsung Bioepis Partners with Takeda to Develop Novel Biologics

August 21, 2017

The first program of this collaboration will focus on the development of a candidate for severe acute pancreatitis.

Pfizer Gets FDA Approval for New Leukemia Drug

August 18, 2017

FDA approves new molecular entity developed by Pfizer for treating a rare form of leukemia in adults.

Biocon Withdraws Breast Cancer Biosimilar Filings in Europe

August 18, 2017

The withdrawal has been attributed to issues at the biotech company’s manufacturing facility.